Week ended October 31, 2026
U.S. Quality Intelligence Brief — Week Ended October 31, 2026
FDA warning letters, revised drug-delivery draft guidance, and PF4 and Medline safety updates address monitoring reliability, CAPA and product performance.
Current Brief
The latest quality signals
Independent commentary on publicly available enforcement actions, recalls, and regulatory developments.
Latest IssueWeek ended November 7, 2026
U.S. Quality Intelligence Brief — Week Ended November 7, 2026
This week’s developments put the supporting evidence behind quality decisions under scrutiny: the integrity of laboratory results, the justification for retesting, the escalation of contamination signals, and the controls supporting product potency. Device alerts and blood-safety communications add a related question: can the controls in place reliably detect or prevent the risk being assessed?
01 / THE BRIEFPritam International: FDA Finds an “Isolated Act” Explanation InadequateRead the analysis and practical carry forward.02 / THE BRIEFNext Medical: Passing Retests Did Not Resolve Failed Environmental ResultsRead the analysis and practical carry forward.03 / THE BRIEFFDA Finalizes Lifecycle Recommendations for CGT Potency AssuranceRead the analysis and practical carry forward.04 / THE BRIEFPlatelet-Sepsis Communication Emphasizes Event-Specific InvestigationRead the analysis and practical carry forward.05 / THE BRIEFRecords Requests Carry Substantive Compliance ConsequencesRead the analysis and practical carry forward.06 / THE BRIEFDevice Alerts Highlight Assembly Controls and Field-Action ScopeRead the analysis and practical carry forward.07 / THE BRIEFFDA Revises HBV Testing Recommendations for Blood DonationsRead the analysis and practical carry forward.
Briefing Archive
Previous issues
Browse every issue online or keep a PDF copy for reference.
Week ended October 24, 2026
U.S. Quality Intelligence Brief — Week Ended October 24, 2026
FDA warning letters address contamination controls, CAPA, data integrity, OOS investigations and batch disposition, alongside updated PCCP resources.
Week ended October 17, 2026
U.S. Quality Intelligence Brief — Week Ended October 17, 2026
FDA warning letters on microbiological data, sterile manufacturing and investigation evidence, plus Par Health and Edwards Lifesciences safety updates.
Week ended October 11, 2026
U.S. Quality Intelligence Brief — Week Ended October 11, 2026
Biosimilar manufacturing-change guidance, Pine and TCI BioCosme warning letters, Nova StatStrip, Unilam, and a Curia data-integrity retrospective.
Week ended October 4, 2026
U.S. Quality Intelligence Brief — Week Ended October 4, 2026
Fresenius Kabi, Greenwich Rx, and Neogen/Sciarra FDA actions illustrate sterile-product control, ingredient suitability, and manufacturing oversight.
Week ended September 27, 2026
U.S. Quality Intelligence Brief — Week Ended September 27, 2026
Retrospective OOS review, visible particulate investigations, packaging-control recurrence, sterile compounding, and the effectiveness of device CAPA systems.
Week ended September 20, 2026
U.S. Quality Intelligence Brief — Week Ended September 20, 2026
The week was moderately active but highly concentrated. FDA’s Warning Letter to Bausch + Lomb is the clear headline and belongs in any current reference file addressing contamination investigations, adverse trending and sterile-product disposition.
Week ended September 13, 2026
U.S. Quality Intelligence Brief — Week Ended September 13, 2026
This week’s quality signal was concentrated but consequential: an FDA Warning Letter describing repeated CGMP observations, unfulfilled remediation commitments, and inadequate executive-management oversight; an injectable-drug recall demonstrating the importance of API-level product bounding; and several device actions involving correction effectiveness, software controls, recurrence analysis, and machine-learning validation.
Put quality intelligence to work
Hamilton Quality helps teams turn quality signals into sound investigations and lasting corrective action.